| Description | COL6A2 Human Pre-designed siRNA Set A contains three designed siRNAs for COL6A2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components COL6A2 siRNA-1: 5 nmol (HPLC) COL6A2 siRNA-2: 5 nmol (HPLC) COL6A2 siRNA-3: 5 nmol (HPLC) siRNA Negative COL6A2 Human Pre-designed siRNA Set A contains three designed siRNAs for COL6A2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components COL6A2 siRNA-1: 5 nmol (HPLC) COL6A2 siRNA-2: 5 nmol (HPLC) COL6A2 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)... Read More | Amyloid β-Protein Fragment 25-35 (Aβ25-35) is derived from the amyloid-β protein.amyloid-β protein, which is mapped to human chromosome 21q21.Aβ25-35 lacks the N-terminal domain and the metal binding site and is majorly generated by proteolytic cleavage of Aβ(1−40Amyloid β-Protein Fragment 25-35 (Aβ25-35) is derived from the amyloid-β protein.amyloid-β protein, which is mapped to human chromosome 21q21.Aβ25-35 lacks the N-terminal domain and the metal binding site and is majorly generated by proteolytic cleavage of Aβ(1−40) peptides. It has a β-sheet and β-turn structure. Amino Acid Sequence Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-MetFunctional domain of Aβ required for both neurotrophic and neurotoxic effects... Read More | Extinction CoeffA280 nm = 1.0 at 1.0 mg/mlGeneral DescriptionProduct is whole polyclonal antiserum from goats immunized with highly purified mouse complement protein. This product is not a purified IgG fraction. Goats are maintained in FDA certified facilities.Physical Characteristics & Extinction CoeffA280 nm = 1.0 at 1.0 mg/mlGeneral DescriptionProduct is whole polyclonal antiserum from goats immunized with highly purified mouse complement protein. This product is not a purified IgG fraction. Goats are maintained in FDA certified facilities.Physical Characteristics & StructureAntibodies present in the antisera are primarily IgG.ApplicationsImmunodiffusion: Effective against NMS and plasma at 1/32 dilution Suggested starting dilutions:Western Blot: 1/500 to 1/1000. Most effective against non-reduced antigen.ELISA: 1/500 to 1/2000... Read More | Inquire | Purity:>95%, by SDS-PAGE visualized with Coomassie® Blue Staining.Description：HSPD1, also known as HSP60, is a member of the chaperonin family. HSPD1 may function as a signaling molecule in the innate immune system. This protein is essential for the folding and assembly of newly Purity:>95%, by SDS-PAGE visualized with Coomassie® Blue Staining.Description：HSPD1, also known as HSP60, is a member of the chaperonin family. HSPD1 may function as a signaling molecule in the innate immune system. This protein is essential for the folding and assembly of newly imported proteins in the mitochondria. It may also prevent misfolding and promote the refolding and proper assembly of unfolded polypeptides generated under stress conditions in the mitochondrial matrix. HSPD1 gene is adjacent to a related family member and the region between the 2 genes functions as a bidirectional promoter. Several pseudogenes have been associated with this gene. Mutations associated with this gene cause autosomal recessive spastic paraplegia 13. Defects in HSPD1 are a cause of spastic paraplegia autosomal dominant type 13 (SPG13). Spastic paraplegia is a degenerative spinal cord disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Defects in HSPD1 are the cause of leukodystrophy hypomyelinating type 4 (HLD4); also called mitochondrial HSP60 chaperonopathy or MitCHAP-60 disease. HLD4 is a severe autosomal recessive hypomyelinating leukodystrophy. HSPD1 is clinically characterized by infantile-onset rotary nystagmus, progressive spastic paraplegia, neurologic regression, motor impairment, profound mental retardation. Death usually occurs within the first two decades of life... Read More |